lapatinib has been researched along with 5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine in 2 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine) | Trials (5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine) | Recent Studies (post-2010) (5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 104 | 14 | 101 |
| Protein | Taxonomy | lapatinib (IC50) | 5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine (IC50) |
|---|---|---|---|
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | Homo sapiens (human) | 1 | |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | Homo sapiens (human) | 1 | |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | Homo sapiens (human) | 10 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.0267 | |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | Homo sapiens (human) | 0.1 | |
| Rapamycin-insensitive companion of mTOR | Homo sapiens (human) | 0.005 | |
| Regulatory-associated protein of mTOR | Homo sapiens (human) | 0.001 | |
| Target of rapamycin complex 2 subunit MAPKAP1 | Homo sapiens (human) | 0.005 | |
| Target of rapamycin complex subunit LST8 | Homo sapiens (human) | 0.003 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aura, C; Baselga, J; Calvo, MT; García-García, C; Grueso, J; Guzmán, M; Ibrahim, YH; Jessen, K; Liu, Y; Pérez, J; Rommel, C; Scaltriti, M; Serra, V; Tabernero, J | 1 |
| Borger, D; Chisholm, S; Foster, R; Growdon, WB; Hernandez, SF; Rueda, BR | 1 |
2 other study(ies) available for lapatinib and 5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine
| Article | Year |
|---|---|
Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Benzoxazoles; Blotting, Western; Breast Neoplasms; Cell Cycle; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Lapatinib; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Nude; Multiprotein Complexes; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Receptor, ErbB-2; TOR Serine-Threonine Kinases; Transcription Factors; Trastuzumab; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoxazoles; Cell Cycle; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Cystadenoma, Serous; Drug Synergism; Female; Gene Amplification; Humans; Lapatinib; Mice; Mice, Inbred NOD; Mice, SCID; Phosphatidylinositol 3-Kinases; Pyrimidines; Quinazolines; Receptor, ErbB-2; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab; Uterine Neoplasms; Xenograft Model Antitumor Assays | 2016 |